Considering that inflammation is involved in the pathological processes of many diseases, and that FGF18 effectively inhibits the NF-κB pathway in LPS-induced ALI model, we can further validate its therapeutic potential in many inflammation-related diseases. This evidence concerns the gene NFKB1 and acute respiratory distress syndrome.